An open-label single-center investigator-initiated exploratory clinical study in patients with refractory or recurrent solid tumors using SBRT as “in situ vaccination”: R-ISV-FOLactis trial. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results